Browsing Department of Drug design and optimization ([HIPS]DDOP) by Authors
Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma.Bihrer, Verena; Waidmann, Oliver; Friedrich-Rust, Mireen; Forestier, Nicole; Susser, Simone; Haupenthal, Jörg; Welker, Martin; Shi, Ying; Peveling-Oberhag, Jan; Polta, Andreas; et al. (2011)MicroRNA-21 (miR-21) is up-regulated in tumor tissue of patients with malignant diseases, including hepatocellular carcinoma (HCC). Elevated concentrations of miR-21 have also been found in sera or plasma from patients with malignancies, rendering it an interesting candidate as serum/plasma marker for malignancies. Here we correlated serum miR-21 levels with clinical parameters in patients with different stages of chronic hepatitis C virus infection (CHC) and CHC-associated HCC.
Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection.Bihrer, Verena; Friedrich-Rust, Mireen; Kronenberger, Bernd; Forestier, Nicole; Haupenthal, Jörg; Shi, Ying; Peveling-Oberhag, Jan; Radeke, Heinfried H; Sarrazin, Christoph; Herrmann, Eva; et al. (2011-09)The liver contains large amounts of microRNA-122 (miR-122), whereas other tissues contain only marginal amounts of this miRNA. MicroRNAs have also been found to circulate in the blood in a cell-free form; their potential as readily accessible disease markers is currently evaluated. Here, we investigated if the serum levels of miR-122 might be useful as disease parameter in patients with chronic hepatitis C virus (HCV) infection.